Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Normal Physiology, Healthy Volunteers, Pain
Interventions: Medoc thermal stimulator, Electric shock stimulator, Cold water bath, Pain assessment performance feedback; Device · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ventricular Tachycardia, Cardiovascular Diseases, Arrythmia, CVD
Interventions: Not listed
Lead sponsor: CardioDx; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Breast Cancer
Interventions: Not listed
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer With Low to Intermediate HER2 Expression
Interventions: Echocardiogram; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Major Depressive Disorder
Interventions: Ketamine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
Interventions: LMB-100, Tofacitinib, Mesothelin Expression; Drug · Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Arrhythmia, Cardiovascular Diseases, Heart Failure, CVD
Interventions: Not listed
Lead sponsor: CardioDx; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Anchorage, Alaska • Palo Alto, California • Minneapolis, Minnesota + 5 more

Conditions: Pain
Interventions: Valdecoxib, COX Inhibitor; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 7 Years to 35 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Carboplatin, Paclitaxel, Gene expression profiling (analysis) of tumor samples; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Heart Failure
Interventions: Simvastatin; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban, Breastfeeding, Breast Milk Collection
Interventions: Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Atrial biopsy; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 20 Years to 99 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Musculoskeletal Pain
Interventions: Emotional Awareness and Expression Therapy (EAET), Cognitive Behavioral Therapy for Chronic Pain (CBT-CP); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rare Diseases, Autism or Autistic Traits, Development Delay, SYT-SSX Fusion Protein Expression, Sleep Disorder, Epilepsy, Generalized, Motor Delay
Interventions: Brain Magnetic Resonance Imaging (MRI), Whole Genome Sequencing, Induced Pluripotential Stem Cells; Diagnostic Test · Genetic · Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 0 Years to 99 Years
Enrollment: 50 participants
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: PI3K-beta Inhibitor GSK2636771; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cutaneous Melanoma
Interventions: Not listed
Lead sponsor: Castle Biosciences Incorporated; Industry
Eligibility: 16 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 4
States / cities: Santa Rosa, California • Frederick, Maryland • Las Vegas, Nevada + 1 more

Conditions: Healthy Volunteers
Interventions: Fast release BRB confection, Intermed release BRB confection, Prolong release BRB confection; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Advanced Cancers Associated With Mesothelin Expression
Interventions: HPN536 Fixed IV 6 to 560 ng/kg, HPN536 1 Prime Step IV 600-1200 ng/kg Target, 2 Prime Step IV 900-14000 ng/kg Target; Biological
Lead sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 12 more

Conditions: Lung Transplantation
Interventions: Not listed
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 8 more

Conditions: Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Interventions: A2B395, xT CDx with HLA-LOH assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: FDC fianlimab+cemiplimab, Cemiplimab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 14 more

Conditions: Advanced Solid Tumors
Interventions: M7437; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: New Haven, Connecticut • Huntersville, North Carolina • Galveston, Texas + 1 more

Search by objective public record fields.

Sociocultural & Biobehavioral Influences on Pain Expression and Assessment

Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial

Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Biomarkers of Fast Acting Therapies in Major Depression

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia

Diagnostic Investigation of Sudden Cardiac Event Risk

Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain

Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling

The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure

Excretion of Rivaroxaban in Human Breast Milk

Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery (GENEXPRO Surg)

A Pragmatic Trial of EAET for Veterans With Chronic Pain

Baker Gordon Syndrome Natural History Study

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes

Black Raspberry Confection in Preventing Oral Cancer in Healthy Volunteers

MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer

Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression

Trifecta-Lung cfDNA-MMDx Study

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors